

1 **Title**

2 Health Utility Value of Overactive Bladder in Japanese Older Adults

3

4 **Authors and affiliations**

5 Takashi Yoshioka, MD, PhD ^{1,2*}

6 Kenji Omae, MD, DrPH ^{3,4}

7 Satoshi Funada, MD, PhD ¹

8 Tetsuji Minami, MD, PhD ⁵

9 Rei Goto, MD, PhD ^{6,7}

10

11 ¹ Health Technology Assessment Unit, Department of Preventive Medicine and Public Health,

12 Keio University School of Medicine, Tokyo, Japan

13 ² Institute of Clinical Epidemiology, Showa University, Tokyo, Japan

14 ³ Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),

15 Fukushima Medical University Hospital, Fukushima, Japan

16 ⁴ Department of Health Promotion and Human Behavior, Graduate School of

17 Medicine/School of Public Health, Kyoto University, Kyoto, Japan

18 ⁵ Division of Quality Assurance Programs, Institute for Cancer Control, National Cancer

19 Center, Tokyo, Japan

20 ⁶ Graduate School of Health Management, Keio University, Kanagawa, Japan

21 ⁷ Graduate School of Business Administration, Keio University, Kanagawa, Japan

22

23 *** Corresponding author**

24 Takashi Yoshioka

25 Health Technology Assessment Unit, Department of Preventive Medicine and Public Health,

26 Keio University School of Medicine, Tokyo, Japan

27 35 Shinano-machi, Shinjuku-ku, Tokyo, 160-8582, Japan

28 Tel:+81-3-5363-3205

29 E-mail: ty5733@keio.jp

30

31 **E-mail address:**

32 Takashi Yoshioka, ty5733@keio.jp

33 Kenji Omae, oranz416@gmail.com

34 Satoshi Funada, sfunada@keio.jp

35 Tetsuji Minami, t.minami.for.urology@gmail.com

36 Rei Goto, reigoto@kbs.keio.ac.jp

37

38 **Word counts:** 3,324

39 **Number of Tables:** 3

40 **Number of Figures:** 3

41 **Number of References:** 30

42

43 **Abstract**

44 **Objectives:** To determine the health utility values (HUVs) of overactive bladder (OAB)
45 among adults aged ≥ 65 years and to assess the HUV decrements (disutilities) of OAB
46 according to its severity.

47 **Methods:** This cross-sectional Internet-based study was conducted between 2 and 9
48 November 2023, with quota sampling with equal probability for each gender and age group
49 (age 65–74 years and ≥ 75 years). OAB was defined as an urgency score of ≥ 2 points and a
50 total score of ≥ 3 points based on the Overactive Bladder Symptom Score. OAB severity was
51 categorized as mild (total score, ≤ 5 points) or moderate-to-severe (total score, 6–15 points).
52 HUVs were measured using the EuroQol 5-Dimension 5-Level value set for the Japanese
53 population. Multivariable linear regression models were fitted to estimate the
54 covariate-adjusted disutilities of OAB, with eight covariates selected based on previous
55 studies.

56 **Results:** Among the 998 participants (51.9% male; median age, 75 years), 158 (15.9%) had
57 OAB, of whom 87 (8.8%) had moderate-to-severe OAB. The mean HUVs for participants
58 with mild and moderate-to-severe OAB were 0.874 and 0.840, respectively, which were
59 lower compared with the HUV for those without OAB (0.913). After adjusting for relevant
60 covariates, disutilities (95% confidence intervals [CIs]) for mild and moderate-to-severe
61 OAB were -0.0334 (-0.0602 to -0.0066) and -0.0591 (-0.0844 to -0.0339), respectively.

62 **Conclusions:** This study examined HUVs in older Japanese adults with and without OAB.
63 The results demonstrate that increased OAB severity is associated with greater disutility.

64
65

66 **Keywords:**

67 Overactive bladder; lower urinary tract symptoms; health utility; health-related quality of life;

68 health economic evaluation

69

70

71 **Introduction**

72 Overactive bladder (OAB), characterized by urinary urgency with or without urinary
73 incontinence, is associated with a substantial disease burden and significant economic impact
74 [1]. The extensive disease burden of OAB includes a decrease in health-related quality of life
75 (HRQoL), mood disorders, and various comorbid or consequential conditions (*e.g.*
76 constipation, fecal incontinence, and irritable bowel syndrome) [2]. The prevalence of OAB
77 increases with age [3]. Furthermore, evidence has demonstrated a longitudinal association
78 between OAB or its treatment with anticholinergics and an increased risk of falls, which are
79 the most critical outcomes in older adults [4]. Consequently, patients with OAB have higher
80 healthcare resource utilization than those without the condition, which contributes to a
81 substantial economic burden [5]. The high global prevalence of OAB, estimated at 15.5%
82 between 2007 and 2020, and its high healthcare cost of \$82.6 billion by 2020 in the United
83 States [1, 6] have drawn significant attention from both policymakers and clinicians
84 worldwide.

85 OAB is widely managed in various healthcare settings, including primary care,
86 urology, and urogynecology [7]. Treatment options for OAB include behavioral therapy and
87 pharmacotherapy, such as antimuscarinic and β -adrenergic agents [7]. Surgical treatments are
88 available for refractory cases, including intradetrusor injection of onabotulinum toxin A,
89 sacral neuromodulation, and percutaneous tibial nerve stimulation [7]. Although these
90 therapeutic options have the potential to relieve patients' symptoms and improve their
91 HRQoL, they also raise concerns about the increasing economic burden on healthcare
92 systems owing to higher treatment costs. Consequently, the importance of effectively
93 allocating finite healthcare resources for the management of OAB is becoming increasingly
94 recognized. In fact, the National Institute for Health and Care Excellence (NICE), an
95 independent organization providing evidence-based guidance to inform healthcare decisions
96 in the United Kingdom (UK), is currently conducting a health economic evaluation (HEE) of
97 vibegron [8], a novel β 3-adrenergic agonist with fewer antimuscarinic side effects compared
98 with traditional OAB medications [9]. Considering the example of the NICE in the UK, new

99 medical technologies for OAB, such as vibegrons, may also be subject to HEEs in other
100 countries, such as Japan.

101 To make HEEs useful for policy decision-making, it is essential to assess their clinical
102 effectiveness (*e.g.* quality-adjusted life years [QALYs]) using generic measures that can be
103 collected for any disease. QALYs are calculated based on health utility values (HUVs)
104 measured using generic preference-based measures (PBMs) rather than disease-specific ones
105 [10]. Importantly, according to the NICE technology appraisal guidance, HUVs should be
106 calculated using the EuroQoL 5-dimensions (EQ-5D), with data collected directly from
107 patients in the country where the evaluation is being conducted (in the case of NICE, the UK)
108 [11]. Previous studies have evaluated the association between OAB symptoms and HUVs
109 using EQ-5D scores in the United States, United Kingdom, Spain, and South Korea [12–14].
110 However, these studies have utilized the older version of the EQ-5D, the three-level EQ-5D
111 version (EQ-5D-3L), which raises concerns about the potential overestimation of positive
112 effects and underestimation of negative effects [15]. The newer version of the EQ-5D, the
113 five-level EQ-5D version (EQ-5D-5L), was developed to overcome the ceiling effects and
114 low sensitivity inherent in EQ-5D-3L [16]. Ideally, the estimation of HUVs based on
115 EQ-5D-5L is essential. However, few studies have used this instrument.

116 To address the unmet needs of global policies regarding HEEs of OAB, this study
117 aimed to describe the HUVs of patients with OAB and assess the impacts of OAB on HUVs
118 using EQ-5D-5L among older adults, the most vulnerable and policy-relevant subgroup,
119 using an Internet-based survey.

120

121 **Participants and methods**

122 *Study design and participants*

123 This cross-sectional study was conducted as part of a research project aimed at developing an
124 EQ-5D-5L value set for the Japanese general older adults [16]. To obtain responses from a
125 sample of older adults, we used a sampling method that ensured a 1:1 ratio for both sex and
126 age groups (age 65–74 and ≥ 75 years). The target sample size was 1,000 participants. The
127 sampling strategy and sample size were determined based on a previous study [17]. All

128 participants were recruited from a survey panel provided by a Japanese Internet research
129 agency (Intage, Inc., <https://www.intage.co.jp/english/>) with approximately 2.6 million
130 panelists and their demographic information. The survey was conducted between 2 and 9
131 November 2023. We designed the survey to prevent participants from proceeding to the next
132 question without providing a valid response, thereby eliminating missing data. The survey
133 questionnaire and response options are presented in **Method S1**.

134

135 *Inclusion and exclusion criteria*

136 All respondents were included in the analysis. However, participants who responded ‘prefer
137 not to answer’ to at least one of the questionnaires except for income items were excluded
138 from this study.

139

140 *Exposures (overactive bladder)*

141 The variable of interest in this study was the presence of OAB. OAB was assessed using the
142 Overactive Bladder Symptom Score (OABSS), a validated questionnaire developed in
143 Japanese [18]. The OABSS is a self-reported questionnaire consisting of four domains
144 (daytime frequency, 0–2 points; nighttime frequency, 0–3 points; urgency, 0–5 points;
145 urgency incontinence, 0–5 points), with a total score of 15 points [18] A higher score
146 indicates more severe OAB symptoms. Based on previous studies and decision modelling on
147 HEEs, OAB was defined as an urgency score of ≥ 2 points and a total score of ≥ 3 points, and
148 the severity of OAB was categorized as mild (OAB with a total score of ≤ 5 points) or
149 moderate-to-severe (OAB with a total score of 6–15 points) [14].

150

151 *Outcomes (health utility values)*

152 Our primary outcome of interest was HUVs measured using the EQ-5D-5L instrument.
153 HUVs are an indicator of an individual’s current health state, where 0 represents death or the
154 worst imaginable health state and 1 represents perfect health, with higher scores indicating
155 better health status [10]. In HEEs, HUVs are calculated using PBMs developed with choice
156 methods (*e.g.* standard gambling or time trade-off) as reference standards [10, 11]. The

157 EQ-5D-5L is a PBM developed by the EuroQoL Group that is used to measure HUVs based
158 on time trade-off methods [10, 11]. Importantly, the EQ-5D-5L has been translated and
159 validated in Japanese, demonstrating substantial reliability and validity for calculating HUVs
160 in the general Japanese population [17].

161 In this study, we used the EuroQoL Visual Analogue Scale (EQ VAS) score as
162 another measure of health utility. The EQ VAS is a scale developed by the EuroQoL Group
163 that measures the current health state using a VAS on a vertically oriented ruler with
164 markings from 0 to 100 [17]. On the EQ-VAS, 0 represents death or the worst imaginable
165 health state, and 100 indicates perfect health. The EQ VAS has often been used in
166 conjunction with the EQ-5D in similar studies [14], and consistent results have been reported.
167 Therefore, we used the EQ-VAS score as an outcome measure for sensitivity analysis in this
168 study.

169 This study used the online formats of the EQ-5D-5L and EQ VAS. The research
170 protocol was pre-registered on the EuroQoL website [16], and permission was obtained to use
171 these instruments. The online versions were administered in strict accordance with the
172 manufacturers' instructions. The EuroQoL registration number for this study is 59331.

173

174 *Covariates*

175 The covariates of interest in this study were demographic, socioeconomic, and health-related
176 variables. These variables were selected from previous studies on OAB that focused on the
177 factors that could potentially influence HUVs. The demographic factors included age
178 (continuous), gender (male or female), and body mass index BMI (continuous).
179 Socioeconomic status included educational attainment (high school education or less and
180 college education or more) and income [6]. As a proxy for income, this study used equivalent
181 household income, derived by adjusting total household income by the square root of
182 household size (then grouped by median, with ranges provided: lower half, JPY 0–2.8
183 million; upper half, JPY \geq 2.9 million), along with a declined to answer category.
184 Health-related factors included smoking status (never/past/current), alcohol consumption
185 (never/past/current), and self-reported coexisting physical and psychiatric comorbidities.

186 Comorbidity data were used to record the presence or absence of the following diseases:
187 hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic
188 kidney disease, stress urinary incontinence, depression, and other psychiatric disorders [5,
189 19–22].

190

191 *Statistical analyses*

192 This study used three analytical approaches. First, a primary analysis was performed targeting
193 all respondents. Second, subgroup analyses were performed, stratified based on sex
194 (male/female) and age (65–74 years old/ ≥ 75 years), assuming that the impacts of OAB on
195 HUVs may vary according to these factors. Third, an exploratory analysis was performed to
196 evaluate the impact of each of the four domains constituting the OAB on HUVs. In all
197 analyses, we initially described the baseline characteristics, including the prevalence of OAB
198 and HUVs. Subsequently, we described the mean (standard deviation [SD]) and median
199 (interquartile range [IQR]) of HUVs based on summary statistics for each group for all
200 analyses. Finally, we estimated the adjusted HUV decrements (disutilities) using a
201 multivariable linear regression analysis after adjusting for covariates. In the multivariable
202 linear regression analysis with ordinal categories (non-OAB/mild OAB/moderate-to-severe
203 OAB), a linear trend test was conducted to assess linearity. To confirm the consistency of the
204 results, a sensitivity analysis was performed in the primary analysis to fit a similar linear
205 regression model using the EQ VAS score as the outcome measure.

206 For all regression models, β coefficients, 95% confidence intervals (CIs), and p -values
207 were calculated. Statistical significance was set at $p < 0.05$. All analyses were performed using
208 STATA version 18.0 (Stata Corp, College Station, Texas, USA).

209

210 *Ethical considerations*

211 All respondents completed online questionnaires after providing digital informed consent
212 indicating their willingness to participate in the survey. Participants received monetary points
213 as an incentive for participation. All the procedures adhered to the ethical guidelines of the
214 1975 Declaration of Helsinki and its subsequent 2013 revision. This study was approved by

215 the Institutional Review Board of Keio University School of Medicine (approval number:
216 20221120). This study followed the Strengthening the Reporting of Observational Studies in
217 Epidemiology (STROBE) guidelines for cross-sectional studies.

218

219 **Results**

220 *Baseline characteristics*

221 Of the 1,099 respondents, 994 (90.7%) were included in the analysis (**Figure 1**). The median
222 age of the participants was 73.2 (SD, 5.3) years, and 516 (51.9%) were male. Regarding
223 socioeconomic indicators, 557 (56.0%) participants had college or higher education.
224 Regarding health-related factors, 107 (10.8%) participants were current tobacco users, 519
225 (52.2%) were current alcohol users, 486 (48.9%) had hypertension, 166 (16.7%) had diabetes,
226 114 (11.5%) had stress urinary incontinence, and 50 (5.0%) had depression. The mean
227 OABSS was 2.7 (SD, 2.2). The mean HUV was 0.90 (SD, 0.11), and the mean EQ VAS
228 score was 75.2 (SD, 17.6) (**Table 1**).

229

230 *Health utility values based on overactive bladder status*

231 **Table 2** presents a summary of the HUVs stratified according to the presence and severity of
232 OAB. The mean HUV for participants without OAB was 0.913 (SD, 0.105), whereas that for
233 those with OAB was 0.855 (SD, 0.145). When categorizing OAB severity into mild and
234 moderate-to-severe OAB, the mean HUV for participants with mild OAB was 0.874 (SD,
235 0.131), and for those with moderate-to-severe OAB, it was 0.840 (SD, 0.155).

236

237 *Disutilities of overall respondents*

238 **Table 3** presents the results of the multivariable linear regression analyses. After adjusting
239 for covariates, the estimated disutility for the presence of OAB was -0.0472 (95% CI,
240 -0.0664 to -0.0279 ; $p < 0.001$). The estimated disutilities for mild and moderate-to-severe
241 OAB were -0.0334 (95% CI, -0.0602 to -0.0066 ; $p = 0.014$) and -0.0591 (95% CI, -0.0844 to
242 -0.0339 ; $p < 0.001$), respectively, indicating a linear relationship (p for trend < 0.001). The
243 sensitivity analysis using the EQ VAS as the outcome variable showed similar results

244 (presence of OAB, $\beta=-5.42$, 95% CI -8.47 to -2.37 , $p=0.001$; mild OAB, $\beta=-4.36$, 95% CI
245 -8.60 to -0.12 , $p=0.044$; moderate-to-severe OAB, $\beta=-6.26$, 95% CI -10.26 to -2.27 ,
246 $p=0.002$; p for trend <0.001).

247

248 *Results of the subgroup analysis*

249 **Tables S1** and **S2** present the baseline characteristics of the sex and age subgroups,
250 respectively. **Table S3** summarizes the HUVs for sex and age subgroups of HUVs. In the sex
251 subgroup, regardless of the presence of OAB, women ($n=478$) had lower mean HUVs than
252 men ($n=516$) (e.g. presence of any OAB: men, 0.872 [SD, 0.128]; women, 0.821 [SD, 0.173]).
253 In the age subgroup, regardless of the presence of OAB, the 75–94-year-old group ($n=502$)
254 showed lower HUVs compared with the 65–74-year-old group ($n=492$) (e.g. presence of any
255 OAB: 65–74 years old, 0.889 [SD, 0.130]; 75–94 years old, 0.829 [SD, 0.152]).

256 The results of the multivariable linear regression analysis are shown in **Figure 2**. In
257 the sex subgroup, a substantial disutility was observed in women with moderate-to-severe
258 OAB ($\beta=-0.1026$; 95% CI, -0.1510 to -0.0542 ; $p<0.001$). In the age subgroup, substantial
259 disutilities were observed in the 75–94-year-old group with mild OAB ($\beta=-0.0688$; 95% CI,
260 -0.1106 to -0.0271 ; $p=0.001$) and moderate-to-severe OAB ($\beta=-0.0664$; 95% CI, -0.1006 to
261 -0.0322 ; $p<0.001$).

262

263 *Results of the exploratory analysis*

264 **Table S4** presents a summary of the HUVs for each domain and the score of the OABSS.
265 The higher OABSS scores indicated the lower mean HUVs in the three domains, excluding
266 urgency urinary incontinence. The results of the multivariable linear regression analysis after
267 rounding scores of $<2.5\%$ of the total are shown in **Figure 3**. After adjusting for covariates,
268 disutilities were observed for each score in the three domains, excluding daytime frequency
269 (e.g. nighttime frequency: 1 point, $\beta=-0.0089$, 95% CI -0.0276 to 0.0099 , $p=0.035$; 2 points,
270 $\beta=-0.0193$, 95% CI -0.0411 to 0.0025 , $p=0.082$; 3 points, $\beta=-0.0409$, 95% CI -0.0682 to
271 -0.0136 , $p=0.003$). A linear relationship between scores and disutilities was observed in all

272 domains, except for daytime frequency (p for trend: nighttime frequency, 0.003; urgency,
273 <0.001; and urgency incontinence, <0.001).

274

275

276 **Discussion**

277 This study described the HUVs of Japanese adults aged ≥ 65 years with or without OAB and
278 estimated the associated disutility of OAB using regression models. The results demonstrated
279 that the mean HUVs of individuals with OAB were lower and the disutility of OAB was
280 greater, depending on the severity of the condition. Subgroup analyses suggested that women
281 and those aged 75 years might experience greater disutility owing to OAB than their
282 counterparts. Furthermore, exploratory analyses indicated the possibility of
283 score-proportional disutility in all domains of the OABSS, except daytime frequency.

284 Previous studies have evaluated the associations of OAB with HUVs in several
285 countries. Kay *et al.* conducted a study estimating EQ-5D-3L-based HUVs from the
286 Incontinence-Specific Quality of Life Questionnaire in 2,505 patients with idiopathic or
287 neurogenic OAB in the United States and Europe [12]. Similarly, Ruiz *et al.* used the
288 Overactive Bladder Symptom and Health-Related Quality of Life Questionnaire in 246
289 patients with OAB to estimate the effects of OAB symptoms on EQ-5D-3L-based HUVs in
290 Spain [13]. Additionally, Kim *et al.* assessed the effects of OAB severity as defined by the
291 OABSS on EQ-5D-3L-based HUVs in 226,867 participants (including 12,303 patients with
292 OAB) from the 2012 Korean Community Health Survey [14]. These studies shared two
293 common features. First, they estimated the associations of OAB with HUVs using OAB
294 measures that are policy-relevant in their respective countries. Second, they employed the
295 EQ-5D-3L for evaluation. These factors significantly influenced the design of this study in a
296 Japanese setting. Second, regarding the choice of OAB measure, we used the OABSS, similar
297 to Kim *et al.*, as it is explicitly used to define OAB in the Japanese OAB guidelines [23]. The
298 OABSS was used to define OAB in a randomized controlled trial evaluating the effects of
299 OAB interventions in Japan [24]. Therefore, decision modelling based on the OABSS is
300 expected when conducting HEEs targeting patients with OAB in Japan. Second, we used the

301 EQ-5D-5L, for which a value set developed and validated by Ikeda *et al.* exists in Japan [17].
302 Evidence suggests that the EQ-5D-3L may potentially overestimate positive associations and
303 underestimate negative associations compared with the EQ-5D-5L in HEEs [15].
304 Consequently, the EQ-5D-5L is recommended for cost-effectiveness evaluations in Japan
305 [25], and our study adhered to this recommendation. This study, which fully considers
306 Japanese clinical practices and healthcare systems, provides HUVs appropriate for HEEs in
307 the Japanese setting. We believe that our approach offers valuable insights for the design of
308 future studies in any country.

309 In this study, the disutility values for mild and moderate-to-severe OABs as defined
310 by the OABSS were -0.034 and -0.0591 , respectively. When referring to the Japanese
311 population norms using the EQ-5D-5L, these disutilities are comparable to those of other
312 chronic conditions that affect HRQoL, such as allergic rhinitis (-0.027), atopic dermatitis
313 (-0.031), and other skin diseases (-0.043) [26]. In a report from Korea, which used the same
314 scale (OABSS) and criteria to define OAB as our study, the covariate-adjusted disutility
315 values for mild OAB, moderate OAB, and severe OAB were -0.029 , -0.089 , and -0.179 ,
316 respectively [14]. The smaller disutility for moderate-to-severe OAB in our study compared
317 to Kim *et al.*'s findings may be explained by differences in the mean age (75 years vs. 45.2
318 years), outcome measure (EQ-5D-5L vs. EQ-5D-3L), and ethnicity (Japanese vs. Korean).
319 However, both studies consistently showed that disutility increased with severity,
320 emphasizing the importance of the associations of OAB with HUVs. Furthermore, our study
321 found high disutility (-0.1026) among female participants with moderate-to-severe OAB in
322 the subgroup analyses. This finding may be supported by the results of EpiLUTS, an Internet
323 survey conducted among individuals aged >40 years in the United States, which showed that
324 a higher proportion of women (39.4%) than men (28.7%) reported moderate-to-severe
325 problems in their patient perception of bladder condition for OAB with bother [27].
326 Additionally, in the subgroup of individuals aged ≥ 75 years, mild and moderate-to-severe
327 OABs were associated with disutility values of similar magnitude (mild OAB -0.0688 vs.
328 moderate-to-severe OAB -0.0664). This finding suggests that the presence of OAB,
329 regardless of severity, may have a substantial impact on older adults who are more likely to

330 be frail than younger respondents. For example, evidence has shown that even in the absence
331 of incontinence, the presence of OAB is a significant risk factor for falls [28].

332 Our study has several strengths. First, we comprehensively provided the descriptive
333 and analytical information necessary for the HEE of OAB, specifically for older adults. The
334 mean and median HUVs at baseline and the disutilities after covariate adjustment for each
335 severity level of OAB are essential information when conducting HEEs. Second, this study
336 estimated disutility by adjusting for a wide range of evidence-based covariates, from
337 socioeconomic to health-related indicators. Third, a subgroup analysis was performed to
338 identify vulnerable populations that are essential for HEEs from the perspective of equity
339 considerations but are understudied [29]. Moreover, our subgroup analysis results provide
340 HUVs that can be referenced in future HEEs, particularly when treatments specifically
341 targeting nocturia or urgent urinary incontinence among the OAB symptoms become
342 available.

343 However, this study has also some limitations. First, as this study utilized an Internet
344 survey, there were concerns regarding the external validity of the results. However, the
345 prevalence of OAB (15.9%) and mean HUV (0.89) in this study did not substantially differ
346 from previous epidemiological data from Japan [26, 30]. Thus, these values are also expected
347 to apply to HEEs. Second, the sample size was limited (approximately 1,000); consequently,
348 there were few individuals with high scores on the OABSS (*e.g.* 2 points for daytime
349 frequency and 4–5 points for urgency urinary incontinence). As a result, it was not possible to
350 differentiate between moderate and severe OAB, and some scores were grouped in the
351 exploratory analysis. Although the number of individuals with such high scores may not be
352 large and may not be considered in actual HEEs, revalidation of our study with a larger
353 sample size would be valuable. Third, there may have been residual confounding factors. For
354 example, orthopedic factors, such as falls and fractures, can be considered in future models.

355 In conclusion, this study examined HUVs in older Japanese adults with and without
356 OAB. The results also demonstrated that increasing the severity of OAB indicated greater
357 disutility, highlighting the substantial effect of OAB on HRQoL. These findings serve as

358 valuable resources for future HEEs of OAB, possibly guiding decision-making in healthcare

359 resource allocation for policymakers.

360

361 **Acknowledgments**

362 This study was supported by the Japan Society for the Promotion of Science KAKENHI grant
363 (grant number: 21K17228) for conducting the survey. This study was also supported by the
364 National Institute of Public Health for the language editing fee and article publishing charge.

365

366 **Conflicts of interest**

367 TY has received the Japan Society for the Promotion of Science (JSPS) KAKENHI grant
368 (grant number: 21K17228) for conducting the survey. RG has received grants for the
369 evaluation of the cost-effectiveness of medicines and medical devices from the National
370 Institute of Public Health, Japan since 2019, which support the consultation fees for the
371 development of search strategies and will support the article publication fee. KO, SF, and TM
372 have no conflicts of interest to declare. The funders did not participate in the study design,
373 data collection, analysis, interpretation, manuscript preparation, review, approval, or decision
374 to submit the manuscript for publication.

375

376 **Data availability statement**

377 The datasets generated and analyzed during the current study are available from the
378 corresponding author upon reasonable request.

379

380 **References**

- 381 1. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and
382 economic burden of urgency urinary incontinence: a systematic review. *Eur Urol* 2014;
383 65: 79–95.
- 384 2. Peyronnet B, Mironska E, Chapple C, *et al.* A comprehensive review of overactive bladder
385 pathophysiology: on the way to tailored treatment. *Eur Urol* 2019; 75: 988–1000.
- 386 3. Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. *Res Rep Urol*
387 2016; 8: 71–6.
- 388 4. Just KS, Schultze KA, Dormann H, *et al.* Use of overactive bladder anticholinergic
389 medications associated with falls leading to emergency department visits: results from
390 the ADRED study. *Eur J Clin Pharmacol* 2023; 79: 1185–93.
- 391 5. Durden E, Walker D, Gray S, Fowler R, Juneau P, Gooch K. The economic burden of
392 overactive bladder (OAB) and its effects on the costs associated with other chronic,
393 age-related comorbidities in the United States. *Neurourol Urodyn* 2018; 37: 1641–9.
- 394 6. Lin W, Li T, Xu Z, *et al.* Association of socioeconomic status and overactive bladder in
395 US adults: a cross-sectional analysis of nationally representative data. *Front Public*
396 *Health* 2024; 12: 1345866.
- 397 7. Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. *Mayo Clin*
398 *Proc* 2020; 95: 370–7.
- 399 8. Project information | Vibegron for treating symptoms of overactive bladder ID6300 |
400 Guidance | NICE. [cited 2024 Jun 5]. Available from:
401 <https://www.nice.org.uk/guidance/indevelopment/gid-ta11348>.
- 402 9. Keam SJ. Vibegron: first global approval. *Drugs* 2018; 78: 1835–9.
- 403 10. Chang EM, Saigal CS, Raldow AC. Explaining health state utility assessment. *JAMA*

- 404 2020; 323: 1085–6.
- 405 11. Foreword | Guide to the methods of technology appraisal, 2013. *Guidance* | NICE. [cited
406 2024 Jun 5]. Available from: <https://www.nice.org.uk/process/pmg9/chapter/foreword>.
- 407 12. Kay S, Tolley K, Colayco D, Khalaf K, Anderson P, Globe D. Mapping EQ-5D utility
408 scores from the Incontinence Quality of Life Questionnaire among patients with
409 neurogenic and idiopathic overactive bladder. *Value Health* 2013; 16: 394–402.
- 410 13. Ruiz MA, Gutiérrez LL, Monroy M, Rejas J. Mapping of the OAB-SF questionnaire onto
411 EQ-5D in Spanish patients with overactive bladder. *Clin Drug Investig* 2016; 36:
412 267–79.
- 413 14. Kim SK, Kim SH. The impact of overactive bladder on health-related quality of life in
414 Korea: based on the results of a Korean Community Health Survey. *Qual Life Res* 2021;
415 30: 1017–24.
- 416 15. Wailoo A, Alava MH, Pudney S, *et al.* An international comparison of EQ-5D-5L and
417 EQ-5D-3L for use in cost-effectiveness analysis. *Value Health* 2021; 24: 568–74.
- 418 16. EuroQol [Internet], 2022 [cited 2024 Jun 10]. Available from:
419 <https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-5l/>. Eq-5d-5l.
- 420 17. Ikeda S, Shiroywa T, Igarashi A, *et al.* *Developing a*, Japanese version of the EQ-5D-5L
421 value set. *J Natl Inst Public Health* 2015; 64: 47–55.
- 422 18. Homma Y, Yoshida M, Seki N, *et al.* Symptom assessment tool for overactive bladder
423 syndrome--overactive bladder symptom score. *Urology* 2006; 68: 318–23.
- 424 19. Welk B, Baverstock R. Is there a link between back pain and urinary symptoms?
425 *Neurourol Urodyn* 2020; 39: 523–32.
- 426 20. Ceyhun G, Erbay G. Relationship between the severity of coronary artery disease and
427 overactive bladder. *Acta Cardiol Sin* 2021; 37: 254–60.

- 428 21. Lai S, Pastore S, Piloni L, *et al.* Chronic kidney disease and urological disorders:
429 systematic use of uroflowmetry in nephropathic patients. *Clin Kidney J* 2019; 12: 414–9.
- 430 22. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome:
431 evaluation and management. *Curr Urol* 2018; 11: 117–25.
- 432 23. The Japanese Continence Society, The Japanese Urological Association, eds. *Clinical*
433 *Guidelines for Overactive Bladder Syndrome*, 3rd edn, 2022.
- 434 24. Funada S, Luo Y, Uozumi R, *et al.* Multicomponent intervention for overactive bladder in
435 women: A randomized clinical trial. *JAMA Netw Open* 2024; 7: e241784.
- 436 25. Center for Outcomes Research and economic evaluation for health, National Institute of
437 Public Health, 2024. *Core to Evidence-Based Health*, Policy [cited 2024 Jun 7].
438 Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance
439 Medical Council. Available from:
440 https://c2h.niph.go.jp/tools/guideline/guideline_en_2024.pdf.
- 441 26. Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health
442 utilities index Mark 3: disutility catalog by disease and symptom in community settings.
443 *Value Health* 2021; 24: 1193–202.
- 444 27. Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive
445 bladder symptoms on health-related quality of life, anxiety, depression, and treatment
446 seeking in the United States: results from EpiLUTS. *Urology* 2012; 80: 90–6.
- 447 28. Omae K, Kurita N, Takeshima T, *et al.* Significance of overactive bladder as a predictor
448 of falls in community dwelling older adults: 1-year followup of the Sukagawa study. *J*
449 *Urol* 2021; 205: 219–25.
- 450 29. Husereau D, Drummond M, Augustovski F, *et al.* Consolidated health economic
451 evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting
452 guidance for health economic evaluations. *Pharmacoeconomics* 2022; 40: 601–9.

- 453 30. Funada S, Kawaguchi T, Terada N, *et al.* Cross-sectional epidemiological analysis of the
454 Nagahama study for correlates of overactive bladder: genetic and environmental
455 considerations. *J Urol* 2018; 199: 774–8.
- 456

457 **Tables**

458 **Table 1** Baseline characteristics of respondents (n=994)

Variables	Category	n	%
Age	Mean (SD)	73.2	(5.3)
	Median [IQR]	75	[68–77]
Sex	Male	516	51.9
BMI	Mean (SD)	22.6	(3.4)
	Median [IQR]	22.3	[20.5–24.3]
Educational attainment	College graduate or more	557	56.0
Equivalent household income	Lower half	409	41.2
	Upper half	360	36.2
	Decline to answer	225	22.6
Smoking status	Never	477	48.0
	Past	410	41.3
	Current	107	10.8
Alcohol consumption	Never	246	24.8
	Past	229	23.0
	Current	519	52.2
Presence of comorbidities	Hypertension	486	48.9
	Dyslipidemia	407	41.0
	Diabetes	166	16.7
	Low back pain	566	56.9
	Ischemic heart disease	91	9.2
	Stroke	63	6.3
	Chronic kidney disease	36	3.6
	Stress urinary incontinence	114	11.5
	Depression	50	5.0
	Other psychiatric disorders	44	4.4
OABSS	Mean (SD)	2.7	(2.2)
	Median [IQR]	2	[1–4]
Health utility value	Mean (SD)	0.90	(0.11)
	Median [IQR]	0.89	[0.83–1]
EQ-VAS score	Mean (SD)	75.2	(17.6)
	Median [IQR]	80	[70–88]

459 **Note.** BMI, body mass index; EQ VAS, EuroQol Visual Analogue Scale; IQR, interquartile range; LUTS,
 460 lower urinary tract symptom; OABSS, Overactive Bladder Symptom Scale; SD, standard deviation.

461

Table 2 Prevalence of OAB and utility values among overall respondents

OAB severity*	n (%)	Mean utility value (SD)	Median utility value [IQR]
Non-OAB	836 (84.1)	0.913 (0.105)	0.894 [0.867–1]
Any OAB	158 (15.9)	0.855 (0.145)	0.885 [0.784–1]
Mild OAB	71 (7.1)	0.874 (0.131)	0.895 [0.823–1]
Moderate-to-severe OAB	87 (8.8)	0.840 (0.155)	0.844 [0.759–1]

Note. IQR, interquartile range; OAB, overactive bladder; SD, standard deviation.

*Mild OAB is defined as domain 3 (urgency) of overactive bladder symptom score (OABSS) \geq 2 and total score of $3 \leq$ OABSS \leq 5, and moderate-to-severe OAB is defined as domain 3 of OABSS \geq 2 and total score of $6 \leq$ OABSS \leq 15.

Table 3 Results of multivariate linear regression models in the main and sensitivity analyses

Variables	Category	β^*	SE	95% CI	p-value	p for trend
Main analysis (outcome measure: EQ-5D-5L)						
Presence or absence of OAB	Non-OAB			Reference		Not applicable
	Any OAB	-0.0472	0.0098	-0.0664 to -0.0279	<0.001	
Based on OAB severity	Non-OAB			Reference		<0.001
	Mild OAB	-0.0334	0.0136	-0.0602 to -0.0066	0.014	
	Moderate-to-severe OAB	-0.0591	0.0129	-0.0844 to -0.0339	<0.001	
Sensitivity analysis (outcome measure: EQ-VAS)						
Presence or absence of OAB	Non-OAB			Reference		Not applicable
	Any OAB	-5.42	1.55	-8.47 to -2.37	0.001	
Based on OAB severity	Non-OAB			Reference		<0.001
	Mild OAB	-4.36	2.16	-8.60 to -0.12	0.044	
	Moderate-to-severe OAB	-6.26	2.04	-10.26 to -2.27	0.002	

Note. EQ-5D-5L, the 5-level EuroQoL 5 dimensions version; EQ VAS, EuroQol Visual Analogue Scale; CI, confidence interval; OAB, overactive bladder; SE, standard error.

* Adjusted for age, sex, body mass index, educational attainment, equivalent household income, smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary incontinence, depression, and other psychiatric disorders).

Figure legends

Figure 1 Flow diagram of this study

Figure 2 Results of multivariate linear regression models in the subgroup analyses


* Adjusted for age, sex, body mass index, educational attainment, equivalent household income, smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary incontinence, depression, and other psychiatric disorders).

Abbreviations: CI, confidence interval; OAB, overactive bladder.

Figure 3 Results of multivariate linear regression models in the exploratory analyses

* Adjusted for age, sex, body mass index, educational attainment, equivalent household income, smoking status, alcohol consumption, and presence of comorbidities (hypertension, dyslipidemia, diabetes, low back pain, ischemic heart disease, stroke, chronic kidney disease, stress urinary incontinence, depression, and other psychiatric disorders).

Abbreviations: CI, confidence interval; OABSS, overactive bladder symptom score.



medRxiv preprint doi: <https://doi.org/10.1101/2024.07.31.24111751>; this version posted August 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

